Morepen Laboratories, a company in the Pharmaceuticals industry, reported revenue of ₹746 crore and net profit of ₹89 crore for the September 2026 quarter.
Morepen Laboratories (NSE: MOREPENLAB-BE) closed at ₹89.80 on 20 Nov 2026, up 99.6% over the past year. Its market capitalisation is ₹4,921 crore and it trades at 26.1 times earnings.
Morepen Laboratories Ltd is engaged in the business of manufacturing, producing, developing and marketing a wide range of Active Pharmaceutical Ingredients (APIs), branded and generic formulations and also the Home Health products.
Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.